top of page
shutterstock_631636766_edited_edited.jpg

Nimble Science Holiday Newsletter

ree


A Message from Our Founders


ree
ree
" 2025 has been a defining year for Nimble Science. Together with our partners and clients, we’ve advanced the boundaries of GI health research, transforming curiosity into clinical and commercial impact. Thank you for your continued trust and collaboration. "

Sabina & Joseph,

Co-Founders, Nimble Science



2025 Highlights



Regulatory Progress


  • Health Canada Class II Medical Device License was granted for the SIMBA™ Capsule in Canada.

  • In both Europe and the US, the SIMBA Capsules were successfully cleared as investigational devices in observational and interventional studies with a variety of patient cohorts.



Strengthening of the Advisory Board and Leadership


  • Prof. Eran Segal, a globally recognized computational biologist at the Weizmann Institute of Science, joined the Nimble Science team as a Scientific Advisor in early 2025. With deep expertise in personalized medicine and nutrition, as well as the complex interplay between genetics, the microbiome, and human health, Prof. Segal has been strategically guiding Nimble in building the first database of the healthy small intestinal microbiome.

  • Corundum Systems Biology joined Nimble Science as a new investor, supporting the company’s mission to advance precision insights into small intestinal health and data.



Scientific Discovery 


  • In 2025, Nimble continued to expand its global footprint, with cumulative deployments exceeding 1,200 capsule ingestions across eight countries in North America and the EU, generating multi-omic data from the small intestine of healthy and diseased cohorts.

  • The MRM Partnered study on Parkinson’s Disease concluded with new insights on microbial composition differences in the small intestine that challenge current targets derived solely from fecal sampling.

  • The Fonterra Partnered study on Protein Digestion demonstrated distinct, peptide signatures in the small intestine, capturing dynamic digestion kinetics across post-prandial windows.

  • Early FMT results from Nimble's Discovery study reveal that the small intestinal microbiota is far more sensitive to antibiotic treatment than the fecal microbiota, highlighting the need to consider regional differences when assessing antibiotic and other interventional impact on the gut microbiome. 

  • The Wageningen University & Research study (TAPIR) demonstrated that SIMBAâ„¢ Capsule can safely and reliably replace trans-nasal catheter aspirates, enabling multi-omic assessment of dietary fat responses with far higher sampling success.



Partnerships Expanded


Cmbio finalized an MSA with Nimble Science as reseller of the SIMBAâ„¢ Capsule in Europe and North America.



Clinical Studies paving new roads


Beyond advancing understanding of GI disorders through direct small-intestinal sampling, the SIMBA™ Capsules are also informing research across systemic conditions—including Diabetes, Liver disease, Pre-eclampsia, Multiple Sclerosis, and Parkinson’s—highlighting the broader role of the gut microbiome in human health.



Platform Launch


The first launch of the SIMBA™ GI Data Platform in mid-2025 enabled our initial customers to benefit from actionable data insights, leveraging Nimble’s growing cohort of healthy participant data for important benchmarking in this de novo dataset.



New Use Cases


Nimble validated new use cases in the timed collection of small intestinal samples to study pharmacokinetics, bioavailability, and food digestion kinetics. This work demonstrates how SIMBA™ Capsule enables time-resolved sampling of the small intestine to directly measure digestion and absorption processes, generating insights that cannot be captured through fecal or systemic sampling alone.



Product Innovation


We introduced new eco-friendly basins for capsule retrieval and a new colon-targeting capsule used in the first clinical investigations. 



Conferences & Community


This year, Nimble Science was featured at leading global conferences, including Probiota America (Vancouver), BioJapan (Yokohama), MANA (Banff), and Global Engage’s Microbiome, R&D and Business Collaborations (USA), among others.


In early 2026, we are invited to present our findings at the Pharmabiotic Research Institute Conference in Belgium and Digestive Disease Week (DDW) in Chicago. The Nimble team will also be attending several events in the first quarter, including Microbiome, Metabolism & Metabolites (Banff), DxPx (Munich), the Microbiome Times Partnering Forum (Copenhagen), and Probiota Global (Dublin). We look forward to seeing you in 2026!





Looking Ahead to 2026

 

  • Launching new clinical studies in oncology and pharmacology to broaden our scientific impact.

  • Expanding our data partnerships across North America, Asia, and Europe to support global-scale discovery.

  • Continuing to evolve the GI Health Data Platform with strengthened analytics and cohort intelligence.



ree
ree
ree


Stay tuned for what's next in 2026...

The launch of SIMBA as a home test kit for clinical use.



ree


"This small bowel microbiome is the key to unlocking treatments for all functional and organic pathologies of the gut. Nimble's solution solves a fundamental problem in translating microbiome science into clinical practice." Dr. James Kinross






SIMBA Studies Global Snapshot


ree
ree



Thank You for Being Part of the Journey

Season’s greetings and best wishes for continued success in the new year.

- The Nimble Science Team





 
 
 
bottom of page